Dr. Eugene Dula, MD

Dr. Dula practices at Quest Diagnostics in West Hills, California.

Dr. Dula's NPI, 1184694523, was assigned on January 26, 2006. Dr. Dula graduated from Icahn School Of Medicine At Mount Sinai in 1983. Dr. Dula holds California license G56131.

Dr. Dula's primary practice is Quest Diagnostics, at 8403 N Fallbrook Ave, West Hills, CA 91304 in Los Angeles County. The practice phone is (740) 289-3508.

Dr. Dula's primary practice is Quest Diagnostics in West Hills, California. Dr. Dula is also affiliated with UCLA West Valley Medical Center. Dmand AI also links Dr. Dula to 2 more hospitals and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dula practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Dula's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Dula is board certified in urology by the American Board of Urology. Dr. Dula is licensed in California.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney disease, kidney removal surgery and kidney stone disease among the conditions Dr. Dula treats.

CMS data shows 37,527 Medicare services from Dr. Dula across 41 procedure codes in 2024, for 1,089 Medicare patients. Medicare paid $487,407 for them.

CMS counts 1,089 Medicare patients who saw Dr. Dula in 2024. The largest group is 75 to 84, with 445 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dula's median patient age at 73, with 16% women.

In 2024, Dr. Dula wrote 2,424 Medicare Part D claims for 679 patients. 91% of them were for generic drugs. CMS names the drug for 2,297 of them, across 32 drugs with 11 or more claims each, at $260,061 in total drug cost. In 2023, CMS named 2,267 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Dula for performance year 2024, reported as part of a group. Dr. Dula accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dula as offering telehealth. CMS counts 12 procedures of prostate resection by Dr. Dula, more than 63% of the clinicians it reports for that procedure.

Dmand AI links 7 papers to Dr. Dula, published from 2008 to 2010. The most frequent topics are Double-Blind Method, Erectile Dysfunction and Administration, Sublingual. Dr. Dula has published most often in J Urol. Dr. Dula's most frequent co-authors are Margaret A. Drehobl, MD, Ming K. Heng, MD and Jonathan W. Simons, MD.

CMS Open Payments shows 320 general payments to Dr. Dula from 42 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 53% of the total. Intuitive Surgical, Inc. paid the most, $3,721.

Dmand AI lists 1 award for Dr. Dula.

Dr. Dula graduated from Icahn School Of Medicine At Mount Sinai in 1983. Dr. Dula is a member of ACS and AUA.

Dr. Dula is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.